Cargando…

Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts

Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from problems of resistance and side-effects. Photoactivatable Pt(IV) prodrugs offer the potential of targeted drug release and new mechanisms of action. We report the synthesis, X-ray crystallographic and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yao, Woods, Julie A, Farrer, Nicola J, Robinson, Kim S, Pracharova, Jitka, Kasparkova, Jana, Novakova, Olga, Li, Huilin, Salassa, Luca, Pizarro, Ana M, Clarkson, Guy J, Song, Lijiang, Brabec, Viktor, Sadler, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: WILEY-VCH Verlag 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280898/
https://www.ncbi.nlm.nih.gov/pubmed/23733242
http://dx.doi.org/10.1002/chem.201300374
_version_ 1782350913724219392
author Zhao, Yao
Woods, Julie A
Farrer, Nicola J
Robinson, Kim S
Pracharova, Jitka
Kasparkova, Jana
Novakova, Olga
Li, Huilin
Salassa, Luca
Pizarro, Ana M
Clarkson, Guy J
Song, Lijiang
Brabec, Viktor
Sadler, Peter J
author_facet Zhao, Yao
Woods, Julie A
Farrer, Nicola J
Robinson, Kim S
Pracharova, Jitka
Kasparkova, Jana
Novakova, Olga
Li, Huilin
Salassa, Luca
Pizarro, Ana M
Clarkson, Guy J
Song, Lijiang
Brabec, Viktor
Sadler, Peter J
author_sort Zhao, Yao
collection PubMed
description Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from problems of resistance and side-effects. Photoactivatable Pt(IV) prodrugs offer the potential of targeted drug release and new mechanisms of action. We report the synthesis, X-ray crystallographic and spectroscopic properties of photoactivatable diazido complexes trans,trans,trans-[Pt(N(3))(2)(OH)(2)(MA)(Py)] (1; MA=methylamine, Py=pyridine) and trans,trans,trans-[Pt(N(3))(2)(OH)(2)(MA)(Tz)] (2; Tz=thiazole), and interpret their photophysical properties by TD-DFT modelling. The orientation of the azido groups is highly dependent on H bonding and crystal packing, as shown by polymorphs 1 p and 1 q. Complexes 1 and 2 are stable in the dark towards hydrolysis and glutathione reduction, but undergo rapid photoreduction with UVA or blue light with minimal amine photodissociation. They are over an order of magnitude more potent towards HaCaT keratinocytes, A2780 ovarian, and OE19 oesophageal carcinoma cells than cisplatin and show particular potency towards cisplatin-resistant human ovarian cancer cells (A2780cis). Analysis of binding to calf-thymus (CT), plasmids, oligonucleotide DNA and individual nucleotides reveals that photoactivated 1 and 2 form both mono- and bifunctional DNA lesions, with preference for G and C, similar to transplatin, but with significantly larger unwinding angles and a higher percentage of interstrand cross-links, with evidence for DNA strand cross-linking further supported by a comet assay. DNA lesions of 1 and 2 on a 50 bp duplex were not recognised by HMGB1 protein, in contrast to cisplatin-type lesions. The photo-induced platination reactions of DNA by 1 and 2 show similarities with the products of the dark reactions of the Pt(II) compounds trans-[PtCl(2)(MA)(Py)] (5) and trans-[PtCl(2)(MA)(Tz)] (6). Following photoactivation, complex 2 reacted most rapidly with CT DNA, followed by 1, whereas the dark reactions of 5 and 6 with DNA were comparatively slow. Complexes 1 and 2 can therefore give rapid potent photocytotoxicity and novel DNA lesions in cancer cells, with no activity in the absence of irradiation.
format Online
Article
Text
id pubmed-4280898
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher WILEY-VCH Verlag
record_format MEDLINE/PubMed
spelling pubmed-42808982015-01-02 Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts Zhao, Yao Woods, Julie A Farrer, Nicola J Robinson, Kim S Pracharova, Jitka Kasparkova, Jana Novakova, Olga Li, Huilin Salassa, Luca Pizarro, Ana M Clarkson, Guy J Song, Lijiang Brabec, Viktor Sadler, Peter J Chemistry Full Papers Platinum diam(m)ine complexes, such as cisplatin, are successful anticancer drugs, but suffer from problems of resistance and side-effects. Photoactivatable Pt(IV) prodrugs offer the potential of targeted drug release and new mechanisms of action. We report the synthesis, X-ray crystallographic and spectroscopic properties of photoactivatable diazido complexes trans,trans,trans-[Pt(N(3))(2)(OH)(2)(MA)(Py)] (1; MA=methylamine, Py=pyridine) and trans,trans,trans-[Pt(N(3))(2)(OH)(2)(MA)(Tz)] (2; Tz=thiazole), and interpret their photophysical properties by TD-DFT modelling. The orientation of the azido groups is highly dependent on H bonding and crystal packing, as shown by polymorphs 1 p and 1 q. Complexes 1 and 2 are stable in the dark towards hydrolysis and glutathione reduction, but undergo rapid photoreduction with UVA or blue light with minimal amine photodissociation. They are over an order of magnitude more potent towards HaCaT keratinocytes, A2780 ovarian, and OE19 oesophageal carcinoma cells than cisplatin and show particular potency towards cisplatin-resistant human ovarian cancer cells (A2780cis). Analysis of binding to calf-thymus (CT), plasmids, oligonucleotide DNA and individual nucleotides reveals that photoactivated 1 and 2 form both mono- and bifunctional DNA lesions, with preference for G and C, similar to transplatin, but with significantly larger unwinding angles and a higher percentage of interstrand cross-links, with evidence for DNA strand cross-linking further supported by a comet assay. DNA lesions of 1 and 2 on a 50 bp duplex were not recognised by HMGB1 protein, in contrast to cisplatin-type lesions. The photo-induced platination reactions of DNA by 1 and 2 show similarities with the products of the dark reactions of the Pt(II) compounds trans-[PtCl(2)(MA)(Py)] (5) and trans-[PtCl(2)(MA)(Tz)] (6). Following photoactivation, complex 2 reacted most rapidly with CT DNA, followed by 1, whereas the dark reactions of 5 and 6 with DNA were comparatively slow. Complexes 1 and 2 can therefore give rapid potent photocytotoxicity and novel DNA lesions in cancer cells, with no activity in the absence of irradiation. WILEY-VCH Verlag 2013-07-15 2013-06-03 /pmc/articles/PMC4280898/ /pubmed/23733242 http://dx.doi.org/10.1002/chem.201300374 Text en © 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Papers
Zhao, Yao
Woods, Julie A
Farrer, Nicola J
Robinson, Kim S
Pracharova, Jitka
Kasparkova, Jana
Novakova, Olga
Li, Huilin
Salassa, Luca
Pizarro, Ana M
Clarkson, Guy J
Song, Lijiang
Brabec, Viktor
Sadler, Peter J
Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts
title Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts
title_full Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts
title_fullStr Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts
title_full_unstemmed Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts
title_short Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts
title_sort diazido mixed-amine platinum(iv) anticancer complexes activatable by visible-light form novel dna adducts
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280898/
https://www.ncbi.nlm.nih.gov/pubmed/23733242
http://dx.doi.org/10.1002/chem.201300374
work_keys_str_mv AT zhaoyao diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT woodsjuliea diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT farrernicolaj diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT robinsonkims diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT pracharovajitka diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT kasparkovajana diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT novakovaolga diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT lihuilin diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT salassaluca diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT pizarroanam diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT clarksonguyj diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT songlijiang diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT brabecviktor diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts
AT sadlerpeterj diazidomixedamineplatinumivanticancercomplexesactivatablebyvisiblelightformnoveldnaadducts